215 related articles for article (PubMed ID: 10408005)
1. [Statins in diabetic hyperlipidemia].
Kirchmair R; Sturm W; Gänzer H; Patsch JR
Wien Med Wochenschr; 1999; 149(5-6):139-43. PubMed ID: 10408005
[TBL] [Abstract][Full Text] [Related]
2. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
Clearfield M
Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
[No Abstract] [Full Text] [Related]
3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
4. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
5. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
[TBL] [Abstract][Full Text] [Related]
7. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
[TBL] [Abstract][Full Text] [Related]
9. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
[TBL] [Abstract][Full Text] [Related]
11. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
[TBL] [Abstract][Full Text] [Related]
13. [Aggressive therapy and combination therapy in severe hyperlipidemia].
Kostner KM
Wien Med Wochenschr; 1999; 149(5-6):146-8. PubMed ID: 10408007
[TBL] [Abstract][Full Text] [Related]
14. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
15. Statins for patients with type 2 diabetes.
Auer J; Berent R; Weber T; Eber B
Lancet; 2004 Nov 27-Dec 3; 364(9449):1933-4. PubMed ID: 15566997
[No Abstract] [Full Text] [Related]
16. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
17. [Dyslipidemia: news in diagnosis and drug therapy].
Cattin L; Spangano F; Fonda M
G Ital Nefrol; 2012; 29 Suppl 54():S5-13. PubMed ID: 22388822
[TBL] [Abstract][Full Text] [Related]
18. Statins for patients with type 2 diabetes.
Pimpinella G; Bertini Malgarini R; Martini N
Lancet; 2004 Nov 27-Dec 3; 364(9449):1933; author reply 1933. PubMed ID: 15566999
[No Abstract] [Full Text] [Related]
19. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.
Argent E; Kainer G; Aitken M; Rosenberg AR; Mackie FE
Pediatr Transplant; 2003 Feb; 7(1):38-42. PubMed ID: 12581326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]